Siriporn Pooripussarakul1, Arthorn Riewpaiboon1* , David Bishai2, Charung Muangchana3 and Sripen Tantivess4 Abstract Background: There is a need to identify rational criteria and set priorities for vaccines. In Thailand, many licensed vaccines are being considering for introduction into the Ex

With HTA gaining ground as a tool for priority-setting globally, it comes as no surprise that, alongside many other questions on the development of the mechanism, countries are trying to find ways to adapt HTA to their particular healthcare system and context. Such was the case the HITAP team found

The coronavirus disease 2019 (COVID-19) pandemic has brought the need for regional collaboration on disease prevention and control to the fore. The review by Durrance-Bagale et al offers insights on the enablers, barriers and lessons learned from the experience of various regional initiatives. Trans

The Delta variant that was first detected in September 2020 in India led to a major outbreak around April 2021. This variant crowded out others due to its higher transmission rate, and it soon became a concern for the rest of the world before the recent surge, on account of the Omicron variant, ecli

A website offering parents advice on vaccines has been ordered to remove information about the MMR jab after claiming it could be linked to autism.Babyjabs.co.uk said the three-in-one jab may be causing “up to 10%” of autism in children in the UK.But the Advertising Standards Authority ruled the cla

COVID-19 has dominated headlines for over a year now and that doesn’t look likely to change in 2021. Health economic and epidemiological modelling has played a key and well-publicised role in informing policymaking decisions across the globe in response to the COVID-19 pandemic. These models and pro

SA IS in the process of preparing for a National Health Insurance (NHI) scheme to reach universal health coverage by 2025. Attaining this goal in a resource-constrained environment will rely in part on understanding which interventions should be prioritised and how resources should be allocated.Our

Watson said that the FDA improperly denied the company’s shared exclusivity on the generic version despite Watson directly following directions received from the regulator.As a result of the FDA’s decision, approval could be delayed for up to six months, Watson said.Watson planned to launch its gene

The National Institute for Health and Clinical Excellence (NICE) says ranibizumab, sold under the brand name Lucentis, is too expensive to use in people with diabetic macular oedema.Charities say they will continue to campaign for the drug to be used. At least 50,000 people in the UK are affected by

As part of a series of events coinciding with the launch of the Gates Reference Case, Tommy Wilkinson (Adviser for Health Economics, NICE International) will be speaking on Tuesday 17 June 2014 at a lunch seminar hosted by the Center for Global Development, Washington DC. If you missed our launch ev